Lower-risk myelodysplastic syndromes
Lower-risk myelodysplastic syndromes rarely turn into leukaemia quickly; the problem is anaemia and the transfusions it demands. Erythropoietin, then luspatercept (COMMANDS) and the telomerase blocker imetelstat (IMerge), free many patients from transfusions for months or years, and lenalidomide does the same for the del(5q) subtype.
Overview
Risk in myelodysplastic syndromes is scored by IPSS-R (blasts, cytogenetics and depth of cytopenias) and now IPSS-M, which adds mutations such as SF3B1 (favourable) and TP53 (adverse). Very low, low and intermediate IPSS-R groups, or IPSS-M low and moderate-low, are lower risk: median survival is measured in years and leukaemic transformation is uncommon, so treatment aims at the cytopenias and their consequences, chiefly transfusion-dependent anaemia with iron overload, and at quality of life. Watchful waiting is right for patients without symptoms.
Anaemia treatment is stepwise. Erythropoiesis-stimulating agents help around half of patients with a serum erythropoietin below 500 U/L. Lenalidomide gives transfusion independence to most patients with del(5q). Luspatercept, a TGF-beta superfamily ligand trap that releases late-stage red cell maturation, was approved in 2020 after MEDALIST for ring-sideroblast disease after erythropoietin failure, and COMMANDS (2023) moved it to first line: 58.5 percent of transfusion-dependent, erythropoietin-naive patients became transfusion independent for at least 12 weeks with a haemoglobin rise, against 31.2 percent on epoetin alfa. Imetelstat, the first telomerase inhibitor, was approved in 2024 after IMerge: in erythropoietin-refractory patients, 39.8 percent became transfusion independent for eight weeks and 28 percent for 24 weeks, against 15 and 3.3 percent on placebo, at the cost of neutropenia and thrombocytopenia.
Other cytopenias have fewer options: thrombopoietin agonists in trials, G-CSF for neutropenic infection, and iron chelation for transfusional iron overload (TELESTO). Allogeneic transplant is deferred until the disease progresses. Elritercept and other activin traps, oral hypomethylating agents at low dose, and drugs against the SF3B1 spliceosome defect are in trials, and IPSS-M is revealing that some patients labelled lower risk carry higher-risk mutations and should be treated accordingly.
State of the art
- Luspatercept is first-line treatment for transfusion-dependent anaemia after COMMANDS, and imetelstat gives a second line that works after erythropoietin fails.
- IPSS-M has shifted treatment for many patients by finding high-risk mutations in disease that looked lower risk.
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Transfusion independence, not survival, is the endpoint that has driven every approval.
Red cards
From the labels and guidelines behind the standard of care. Your team's thresholds win.- Emergency services nowBleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
- Emergency services nowBlood clot (lenalidomide, pomalidomide, thalidomide)
A swollen painful calf, or sudden breathlessness with chest pain; venous and arterial thromboembolism is a boxed warning and blood-thinning prophylaxis is recommended.
- Check before combiningKidneys: Lenalidomide
Dose by creatinine clearance: 10 mg daily for CrCl 30-60, 15 mg every other day below 30, 5 mg daily on dialysis.
- Good to knowAnaemia
A shortage of red blood cells or haemoglobin, causing tiredness and breathlessness. In cancer it comes from the disease itself (marrow infiltration, bleeding, inflammation), from chemotherapy suppressing the marrow, and from some targeted drugs.
- Good to knowVenous thromboembolism (VTE)
Blood clots in the leg veins or lungs. Cancer makes blood clot more easily and some treatments (IMiDs, anti-VEGF drugs, hormone therapy, central lines, surgery) add risk; clots are the second commonest cause of death in cancer patients after the cancer itself.
See all on the product pages:AzacitidineImetelstatLenalidomideLuspatercept·Printable cards in the navigator
Anatomy and lymph node drainage
- Bone marrow (leukaemia, MDS, MPN, myeloma)
- Lymph node germinal centre (lymphomas)
- Spleen
- Blood (leukaemic phase)
- Lytic bone lesions (myeloma)
- Skin and extranodal sites
- Nodes: cervical
- Nodes: axillary
- Nodes: mediastinal
- Nodes: para-aortic and mesenteric
- Nodes: inguinal
Leukaemias, myeloma and MDS live in the marrow and blood; lymphomas grow in lymph nodes and spleen. The node stations are the disease map, not a route of spread, and staging counts them.
- Bone marrow (leukaemia, MDS, MPN, myeloma)MDS with low blasts, IPSS-R very low or low · MDS with SF3B1 mutation and ring sideroblasts (luspatercept) · MDS with isolated del(5q) (lenalidomide) · Transfusion-dependent lower-risk MDS after erythropoietin failure (imetelstat, luspatercept) · Hypoplastic MDS (immunosuppression) · IPSS-R intermediate MDS reclassified by IPSS-M
- Lymph node germinal centre (lymphomas)
- Spleen
- Blood (leukaemic phase)
- Lytic bone lesions (myeloma)
- Skin and extranodal sites
- cervical
- axillary
- mediastinal
- para-aortic and mesenteric
- inguinal
In lymphoma the node stations are the disease itself; staging (Ann Arbor / Lugano) counts how many regions and sides of the diaphragm are involved.
Same organ: Marginal zone lymphoma, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Primary mediastinal (thymic) large B-cell lymphoma, Leukaemia (all types), Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia (CML), Diffuse large B-cell lymphoma, Follicular lymphoma, Hodgkin lymphoma, Mantle cell lymphoma, Multiple myeloma, Non-Hodgkin lymphoma (all types), Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Polycythaemia vera (PV), Essential thrombocythaemia (ET), Waldenström macroglobulinaemia, Hairy cell leukaemia, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Burkitt lymphoma, HIV-associated (AIDS-related) lymphomas, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Systemic mastocytosis, Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, Langerhans cell histiocytosis (LCH), Post-transplant lymphoproliferative disorder (PTLD), FLT3-mutated acute myeloid leukaemia, IDH1- and IDH2-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, Acute promyelocytic leukaemia, Acute myeloid leukaemia in older or unfit patients, Smouldering multiple myeloma, Newly diagnosed multiple myeloma, transplant-eligible, Newly diagnosed multiple myeloma, transplant-ineligible, Relapsed or refractory multiple myeloma, Plasma cell leukaemia, Higher-risk myelodysplastic syndromes, Chronic lymphocytic leukaemia, first treatment, Relapsed or refractory chronic lymphocytic leukaemia, Richter transformation of chronic lymphocytic leukaemia, Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia, accelerated and blast phase, Primary myelofibrosis
About two-thirds of people with myelodysplastic syndromes have lower-risk disease by IPSS-R; most are over 70, and anaemia rather than leukaemia is what shapes their lives, with many needing regular transfusions.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Observation with blood counts every three to six months; no treatment.
Luspatercept for ring-sideroblast or SF3B1-mutated disease and for transfusion-dependent patients (COMMANDS); erythropoiesis-stimulating agent where serum erythropoietin is below 500 U/L; lenalidomide for del(5q).
Imetelstat (IMerge); luspatercept if not yet used; low-dose hypomethylating agent; trials of elritercept and other agents.
Red cell transfusion to symptoms, iron chelation once ferritin is persistently high, G-CSF for recurrent neutropenic infection, platelet transfusion for bleeding.
Subtypes & biomarkers
top- MDS with low blasts, IPSS-R very low or low
- MDS with SF3B1 mutation and ring sideroblasts (luspatercept)
- MDS with isolated del (5q) (lenalidomide)
- Transfusion-dependent lower-risk MDS after erythropoietin failure (imetelstat, luspatercept)
- Hypoplastic MDS (immunosuppression)
- IPSS-R intermediate MDS reclassified by IPSS-M
- IPSS-R and IPSS-M scores
- Serum erythropoietin level
- Ring sideroblasts and SF3B1 mutation
- del (5q)
- Transfusion burden
- Serum ferritin and iron overload
- TP53 and other adverse mutations on IPSS-M
How often this target appears
- 1997International Prognostic Scoring System for MDS
- 2005Lenalidomide produces transfusion independence in del(5q) MDS
- 2012IPSS-R revised scoring system
- 2020Luspatercept approved after MEDALIST
- 2022IPSS-M adds mutations to risk scoring
- 2023COMMANDS: luspatercept beats epoetin alfa in first line
- 2024Imetelstat approved after IMerge: the first telomerase inhibitor
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 12 changes by month →- 2026-09-17This recordLower-risk myelodysplastic syndromesFacts on this page last checked
When this page itself was last checked or edited.
- 2024MilestoneImetelstatImetelstat approved after IMerge: the first telomerase inhibitor
A milestone in how this cancer is treated.
- 2023MilestoneLuspaterceptCOMMANDS: luspatercept beats epoetin alfa in first line
A milestone in how this cancer is treated.
- 2022MilestoneLower-risk myelodysplastic syndromesIPSS-M adds mutations to risk scoring
A milestone in how this cancer is treated.
- 2020MilestoneLuspaterceptLuspatercept approved after MEDALIST
A milestone in how this cancer is treated.
- 2012MilestoneDisease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)IPSS-R revised scoring system
A milestone in how this cancer is treated.
What is in development for Lower-risk myelodysplastic syndromes, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Technologies being tested · 1
Trials under way · 4
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B · phase 3 · Takeda
- Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) · phase 1/2 · Rigel Pharmaceuticals
- RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms · phase 2 · GCP-Service International West GmbH
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia · phase 1/2 · Disc Medicine, Inc
Open problems and what is being done
No approved treatment for thrombocytopenia or neutropenia in lower-risk disease.
Whether early disease-modifying treatment changes the natural history rather than the transfusion count.
Iron overload management and quality of life are under-studied.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Expert centres
topExpert centres
Los Angeles, CA · cancer center | United States | 0 | 318 | 3,917 | - | ||
Melbourne · research institute | Australia | none recorded | 0 | 298 | 3,639 | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Lower-risk myelodysplastic syndromes but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
Questions to ask
topQuestions to ask your oncologist about Lower-risk myelodysplastic syndromes
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example IPSS-R and IPSS-M scores, Serum erythropoietin level, Ring sideroblasts and SF3B1 mutation, del, Transfusion burden), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include MDS with low blasts, IPSS-R very low or low, MDS with SF3B1 mutation and ring sideroblasts, MDS with isolated del.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Asymptomatic, no transfusions
- For my situation (asymptomatic, no transfusions), which of the standard options do you recommend and why?Why: Guideline options include: Observation with blood counts every three to six months; no treatment.
Anaemia, first line
- For my situation (anaemia, first line), which of the standard options do you recommend and why?Why: Guideline options include: Luspatercept for ring-sideroblast or SF3B1-mutated disease and for transfusion-dependent patients (COMMANDS); erythropoiesis-stimulating agent where serum erythropoietin is below 500 U/L; lenalidomide for del(5q).
- Am I a candidate for Luspatercept, Epoetin alfa, Darbepoetin alfa or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Anaemia after erythropoietin or luspatercept failure
- For my situation (anaemia after erythropoietin or luspatercept failure), which of the standard options do you recommend and why?Why: Guideline options include: Imetelstat (IMerge); luspatercept if not yet used; low-dose hypomethylating agent; trials of elritercept and other agents.
- Am I a candidate for Imetelstat, Luspatercept, Azacitidine, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B and Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Supportive care
- For my situation (supportive care), which of the standard options do you recommend and why?Why: Guideline options include: Red cell transfusion to symptoms, iron chelation once ferritin is persistently high, G-CSF for recurrent neutropenic infection, platelet transfusion for bleeding.
Any stage
- Are there clinical trials I could join, for example of Luspatercept, Imetelstat, A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B, Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “No approved treatment for thrombocytopenia or neutropenia in lower-risk disease”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Whether early disease-modifying treatment changes the natural history rather than the transfusion count”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Newly diagnosed? Read the first 60 days with Lower-risk myelodysplastic syndromes, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
6drugs
6companies
5terms
3trials
4key papers
2IMerge validated telomerase as a drug target in cancer, decades after its discovery, and gave a second-line option for MDS patients whose anaemia no longer responds to erythropoietin or luspatercept. The hint of clonal reduction is what makes the drug interesting beyond transfusion counts. Cytopenias require close monitoring in the first cycles.
COMMANDS moved luspatercept from second line (after ESA failure, MEDALIST trial) to first line, offering transfusion-dependent lower-risk MDS patients a better chance of transfusion freedom from the start. It changed guidelines and labels in 2023. Erythropoietin remains a reasonable and cheaper option for patients without ring sideroblasts or with low transfusion burden.
Latest papers
topQuery for this cancer: (TITLE:"Lower-risk myelodysplastic syndromes" OR ABSTRACT:"Lower-risk myelodysplastic syndromes" OR TITLE:"Low-risk MDS" OR ABSTRACT:"Low-risk MDS" OR TITLE:"IPSS-R very low, low and intermediate MDS" OR ABSTRACT:"IPSS-R very low, low and intermediate MDS" OR TITLE:"Lower-risk myelodysplastic neoplasms" OR ABSTRACT:"Lower-risk myelodysplastic neoplasms" OR TITLE:"Transfusion-dependent lower-risk MDS" OR ABSTRACT:"Transfusion-dependent lower-risk MDS") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Lower-risk myelodysplastic syndromes, not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerPrimary myelofibrosis
Shares Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia, Epoetin alfa, Anaemia, Luspatercept and the tag subtype-page.
- CancerHigher-risk myelodysplastic syndromes
Shares Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC), Transfusion support and anaemia management, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag subtype-page.
- CancerAcute myeloid leukaemia in older or unfit patients
Shares Transfusion support and anaemia management, Azacitidine and the tag subtype-page.
- CancerNewly diagnosed multiple myeloma, transplant-ineligible
Shares Transfusion support and anaemia management, Lenalidomide and the tag subtype-page.
- CancerAcute promyelocytic leukaemia
Shares Transfusion support and anaemia management and the tag subtype-page.
- CancerMarginal zone lymphoma
Shares Lenalidomide and the tag subtype-page.
- CancerIDH1- and IDH2-mutated acute myeloid leukaemia
Shares Azacitidine and the tag subtype-page.
- CancerFLT3-mutated acute myeloid leukaemia
Shares Azacitidine and the tag subtype-page.